reports
Zealand Pharma major shareholder announcement: Van Herk Investments B....
Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Company announcement – No. 17 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, July 18, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 18 July 2025 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder: As of 17 July 2025, Van Herk Investments B.V. (Dutch re...
Total number of shares and voting rights in Zealand Pharma as of June ...
Total number of shares and voting rights in Zealand Pharma as of June 30, 2025 Company announcement – No. 16 / 2025 Total number of shares and voting rights in Zealand Pharma as of June 30, 2025 Copenhagen, Denmark, June 30, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar mo...
- Jacob Mekhael
ADA amylin monotherapy highlights Zealand, Novo, Lilly
The American Diabetes Association (ADA) conference was held 20-23 June, 2025 and contained a number of highly anticipated updates in the obesity pipeline. We summarise the key amylin monotherapy datasets in this note including data from Zealand from petrelintide's phase 1b showing higher weight loss in females, Lilly's eloralintide full presentation, which shows that the higher doses which showed competitive weight loss and generated excitement following the abstract release also come with heada...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Thomas Couvreur
- Jacob Mekhael
Zealand Pharma We think sell off is overdone, jury is still out on elo...
Following the release of phase 1 MAD results for eloralintide (Lilly, no coverage) showing 11.3% weight loss at 12 weeks, Zealand's stock has declined -18% over the last 5 days. While the results look competitive vs. Zealand's petrelintide at first glance, key details on dosing and GI side effects per treatment arm remain undisclosed. We note that, given their similar activity on both amylin and calcitonin receptors, cagrilintide's long term 68 week data de-risks petrelintide's development. This...
- Jacob Mekhael
Zealand Pharma Dapiglutide phase 1b shows strong weight loss, plans to...
Zealand announced topline results from part 2 of the phase 1b multiple ascending dose (MAD) trial of dapiglutide (long-acting GLP-1/GLP-2 receptor dual agonist) in overweight/obese participants, which showed 11.4% (placebo adjusted) weight loss, coming in higher than semaglutide, and closer to tirzepatide at a similar timepoint in the phase 3 (STEP-1 and SURMOUNT-1) trials. By targeting GLP-2 on top of GLP-1, dapiglutide aims to address low grade inflammation on top of weight loss. As such, we b...
- Hilde Van Boxstael
- Jacob Mekhael
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
Zealand Pharma announces positive topline results from 28-week Phase 1...
Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Company announcement – No. 15 / 2025 Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Body weight reductions of a mean of 11.6% after 28 weeks with dapiglutide escalated up to 26 mg, with 95% of trial participants being male, a median baseline BMI of 28.5 kg/m2, and no lifestyle modificationsTreatment with dapiglutide was assessed to be safe and well-tolerated with gastrointestinal a...
Zealand Pharma increases its share capital as a result of the exercise...
Zealand Pharma increases its share capital as a result of the exercise of employee warrants Company announcement – No. 14 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, June 6, 2025 – Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 292,508 divided into 292,508 new shares with a nominal value ...
- Jacob Mekhael
Zealand Pharma FIRST LOOK: Submits glepaglutide MAA to the EMA in shor...
Zealand announced the submission of a marketing authorization application (MAA) to the European Medicines Agency (EMA) for glepaglutide twice weekly (long-acting GLP-2 analog) in adults with short bowel syndrome (SBS). Looking ahead, we look forward to the initiation of the confirmatory phase 3 trial in the US, expected in 2H25. Beyond glepaglutide, which represents a small fraction of our SOTP, additional phase 1b data (higher dosing and longer treatment) for dapiglutide (long acting GLP-1/GLP-...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Wim Lewi
Zealand Pharma submits Marketing Authorization Application to the Euro...
Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome Press release – No. 10 / 2025 Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome Copenhagen, Denmark, June 2, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the submission of a Marketing Authorization Application (MAA) to the European...
Transactions in Zealand Pharma shares and/or related securities by per...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Company announcement – No. 13 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, May 27, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received infor...
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
Zealand Pharma continues to strengthen strategic leadership of innovat...
Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer Press release – No. 9 / 2025 Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer Steven will lead the regulatory and development strategies that position Zealand Pharma at the forefront of innovation in the management of obesity and other related complications He joins CMO David Kendall and recently...
Zealand Pharma to participate in upcoming healthcare investor conferen...
Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025 Press release – No. 8 / 2025 Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025 Copenhagen, Denmark, May 12, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that the company will participate in the following healthcare investor conferences in May and June 2025: Bank of America Global Healthcare Conference, May 13-15 in L...
Zealand Pharma announces closing of collaboration and license agreemen...
Zealand Pharma announces closing of collaboration and license agreement with Roche Company announcement – No. 12 / 2025 Zealand Pharma announces closing of collaboration and license agreement with Roche Copenhagen, Denmark, May 9, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces that all closing conditions in the collaboration and license agreement with Roche have been satisfied, including regulatory conditions, and the ag...
- Hilde Van Boxstael
- Jacob Mekhael
- Michiel Declercq
- Thomas Vranken
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
Zealand Pharma Uneventful 1Q25 results, dapi phase 1 higher dose data ...
Zealand reported uneventful 1Q25 results with a cash position of DKK 8,545m to be supplemented with a $1.4b (approx. DKK 9.24b) upfront from Roche in 2Q25. Pipeline timelines were reiterated, and while the later stage datasets are expected in 1H26, we look forward to results from the higher dose cohort from the phase 1b trial of dapiglutide (GLP-1/GLP-2 analog) in overweight/obese patients in 2Q25. In addition, we expect read-through from cagrisema's (GLP-1/amylin analog) full dataset potentiall...
Zealand Pharma Announces Financial Results for the First Three Months ...
Zealand Pharma Announces Financial Results for the First Three Months of 2025 Company announcement – No. 11 / 2025 Zealand Pharma Announces Financial Results for the First Three Months of 2025 Significant progress in the clinical pipeline, strengthening of organizational capabilities, and strategic partnership for petrelintide create strong foundation for accelerated growth. Entered historic and transformative partnership with Roche to co-develop and co-commercialize petrelintide as a future foundational therapy for weight management and rapidly expand into related indications, aiming to...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.